There Is a Place forDigoxin
Xiang Li,Luisa Kemmer,Xiaoli Zhang,M. Kircher,A. Buck,H. Wester,M. Hacker,C. Lapa
2018-01-01
Abstract:(Biograph mCT 64; Siemens, Erlangen, Germany) before and after 1 cycle of treatment (Lu: 15.2 and 7.8 GBq, respectively; Y: 5.1 2.0 GBq). The median time interval between baseline and follow-up GaPentixafor PET/CT was 98 days (range: 56 to 126 days). Eight arterial segments were screened for increased Ga-Pentixafor uptake, including both carotids, the aortic arch, the ascending and descending aorta, the abdominal aorta, and both iliac arteries. Briefly, a 3-dimensional volume of interest was drawn along the arterial wall with present focal uptake of GaPentixafor. For analysis of follow-up scans, the same lesions that were detected at baseline were considered. Maximum standardized uptake values (SUVmax) were derived from these volumes of interest, and the mean of blood-pool radioactivity (SUVblood) was determined from 3 volumes of interest in the superior vena cava. The normalized maximum tissue-to-blood ratio (TBRmax) was calculated by dividing SUVmax from tissue with SUVblood from the blood pool. Continuous variables were recorded as mean SD. The mean TBRmax of Ga-Pentixafor pre-therapy and post-therapy were retrospectively assessed using the paired Student’s t-test. Two-sided p values of <0.05 were considered significant. At baseline, 24 arterial lesions with focal uptake of Ga-Pentixafor (in a single patient, 9 focal lesions could be analyzed; in the remainder, 5 [n 1⁄4 1), 4 [n 1⁄4 1], and 3 [n 1⁄4 2] lesions were assessed, respectively) were detected, and 3 of them (13%) showed arterial macrocalcification (with CT Hounsfield units $130). ERT resulted in a substantial decrease of uptake ratios in 18 of 24 (75%) of initially Ga-Pentixafor– positive lesions (mean TBRmax of the 24 lesions: 1.8 0.3 vs. 1.4 0.4; p 1⁄4 0.08) (Figure 1). Post-therapeutic C-reactive protein levels did not differ significantly from pre-therapeutic values (post-therapy: 0.32 0.20 mg/dl vs. pre-therapy: 0.24 0.12 mg/dl; p 1⁄4 0.27). To summarize, in a small cohort of patients experiencing multiple myeloma, targeted ERT appeared to induce a reduction of arterial CXCR4 expression, as determined by Ga-Pentixafor PET/CT. Although this initial observation suffers from small sample size, retrospective design, and lack to histologic confirmation, the interaction of CXCR4-directed treatment (also using non-radionuclide-based receptor antagonists) with vascular inflammatory pathophysiology should be considered for future applications and might open a new therapeutic option for high-risk atherosclerosis. Xiang Li, PhD Luisa Kemmer, MD Xiaoli Zhang, MD Malte Kircher, MD Andreas K. Buck, MD Hans-Jürgen Wester, PhD Marcus Hacker, MDy *Constantin Lapa, MDy *Department of Nuclear Medicine University Hospital Würzburg Oberdürrbacherstrasse 6 97080 Würzburg Germany E-mail: lapa_c@ukw.de Twitter: @Uni_WUE, @MedUni_Vienna